HLA-DRA
HLA class II histocompatibility antigen, DR alpha chain
Also known as: DRA_HUMAN, HLA-DRA1
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P01903
- Gene
- HLA-DRA
- Ensembl
- ENSG00000204287
- Chromosome
- 6
- Canonical length
- 254 aa
- Protein class
- Plasma proteins, Predicted membrane proteins
OverviewNCBI Gene
HLA-DRA is one of the HLA class II alpha chain paralogues. This class II molecule is a heterodimer consisting of an alpha and a beta chain, both anchored in the membrane. This molecule is expressed on the surface of various antigen presenting cells such as B lymphocytes, dendritic cells, and monocytes/macrophages, and plays a central role in the immune system and response by presenting peptides derived from extracellular proteins, in particular, pathogen-derived peptides to T cells. The alpha chain is approximately 33-35 kDa and its gene contains 5 exons. Exon 1 encodes the leader peptide, exons 2 and 3 encode the two extracellular domains, and exon 4 encodes the transmembrane domain and the cytoplasmic tail. DRA does not have polymorphisms in the peptide binding part and acts as the sole alpha chain for DRB1, DRB3, DRB4 and DRB5. [provided by RefSeq, Aug 2020]
Canonical amino-acid sequenceUniProt
254 residues, UniProt reviewed canonical sequence.
>P01903|HLA-DRA
1 MAISGVPVLG FFIIAVLMSA QESWAIKEEH VIIQAEFYLN PDQSGEFMFD FDGDEIFHVD
61 MAKKETVWRL EEFGRFASFE AQGALANIAV DKANLEIMTK RSNYTPITNV PPEVTVLTNS
121 PVELREPNVL ICFIDKFTPP VVNVTWLRNG KPVTTGVSET VFLPREDHLF RKFHYLPFLP
181 STEDVYDCRV EHWGLDEPLL KHWEFDAPSP LPETTENVVC ALGLTVGLVG IIIGTIFIIK
241 GLRKSNAAER RGPLLocalizationUniProt · AlphaFold · HPA
Whether an antibody against HLA-DRA can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.39
- Highest tissue expression
- 1,197 nTPM
Expression across tissuesHPA
Tissue
- lymph node: 1,197 nTPM
- spleen: 1,077 nTPM
- lung: 931 nTPM
- tonsil: 754 nTPM
- small intestine: 700 nTPM
- adipose tissue: 509 nTPM
Single-cell type
- cdc: 2,677 nCPM
- macrophages: 502 nCPM
- microglia: 439 nCPM
- endometrial secretory cells: 417 nCPM
- monocytes: 371 nCPM
- kupffer cells: 367 nCPM
Immune cell
- naive B-cell: 420 nTPM
- intermediate monocyte: 409 nTPM
- memory B-cell: 380 nTPM
- non-classical monocyte: 255 nTPM
- plasmacytoid DC: 231 nTPM
- classical monocyte: 210 nTPM
Brain region
- midbrain: 11 nTPM
- medulla oblongata: 7.4 nTPM
- white matter: 4.9 nTPM
- pons: 4 nTPM
- thalamus: 2.2 nTPM
- basal ganglia: 2 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about HLA-DRA.
Disease | ImmuneIEDB
Conditions an epitope on HLA-DRA was assayed in.
- multiple sclerosis T cell
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.59
- gnomAD pLI
- 0.52
- gnomAD missense Z
- 1.17
- DepMap mean gene effect
- 0.08
- DepMap dependency class
- selective
OntologyGO
Biological processes
- adaptive immune response
- antigen processing and presentation of endogenous peptide antigen via MHC class II
- antigen processing and presentation of exogenous peptide antigen via MHC class II
- cognition
- immune response
- myeloid dendritic cell antigen processing and presentation
- peptide antigen assembly with MHC class II protein complex
- positive regulation of CD4-positive, alpha-beta T cell activation
- positive regulation of CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation
- positive regulation of immune response
- positive regulation of memory T cell differentiation
- positive regulation of T cell activation
- positive regulation of T cell mediated cytotoxicity
- regulation of T-helper cell differentiation
- antigen processing and presentation of peptide or polysaccharide antigen via MHC class II
Molecular functions
- MHC class II protein complex binding
- peptide antigen binding
- polysaccharide binding
- T cell receptor binding
Cellular components
- autolysosome membrane
- cell surface
- clathrin-coated endocytic vesicle membrane
- early endosome membrane
- endocytic vesicle membrane
- ER to Golgi transport vesicle membrane
- extracellular exosome
- Golgi membrane
- immunological synapse
- late endosome membrane
- lumenal side of endoplasmic reticulum membrane
- lysosomal membrane
- lysosome
- MHC class II protein complex
- plasma membrane
- trans-Golgi network membrane
- transport vesicle membrane
Protein domainsUniProt · Pfam · InterPro
- MHC class II, alpha chain, N-terminal
- Immunoglobulin/major histocompatibility complex, conserved site
- Immunoglobulin C1-set
- Immunoglobulin-like domain
- MHC classes I/II-like antigen recognition protein
- Immunoglobulin-like fold
- MHC class II, alpha/beta chain, N-terminal
- Immunoglobulin-like domain superfamily
- Major Histocompatibility Complex/Immunoglobulin
- Class II histocompatibility antigen, alpha domain
- Immunoglobulin C1-set domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of HLA-DRA in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads HLA-DRA as an antibody target. Whether an autoantibody or antibody against HLA-DRA could matter depends on whether native HLA-DRA is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
HLA-DRA is annotated at the cell surface, where native HLA-DRA is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label HLA-DRA as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...